Trial Profile
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATE(S) AGAINST INFECTIOUS RESPIRATORY ILLNESSES, INCLUDING COVID-19 AND RSV, IN HEALTHY INDIVIDUALS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; PF 06928316 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections; Respiratory syncytial virus infections; SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pfizer
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 11 Dec 2023 Planned End Date changed from 26 Dec 2023 to 2 Jan 2024.
- 11 Dec 2023 Planned primary completion date changed from 26 Dec 2023 to 2 Jan 2024.